← Back
Data updated: Mar 10, 2026
JAZZ
NeurologyOncologyGastroenterology
JAZZ is a specialty pharmaceutical company focused on Neurology, Oncology, Gastroenterology. Key products include XYWAV.
2004
Since
4
Drugs
-
Trials
6
Approved (2yr)
Key Drugs
Recent Activity
ZEPZELCA 2025-10-02
Efficacy
XYWAV 2025-07-28
REMS
XYWAV 2025-05-21
REMS
ZEPZELCA 2025-04-30
Labeling
XYWAV 2024-11-18
REMS
XYWAV 2024-05-22
REMS
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 50%
0 drugs Phase 3: 11 Phase 2: 10 Phase 1: 1
Oncology 41%
1 drugs Phase 3: 4 Phase 2: 10 Phase 1: 11
Gastroenterology 6%
0 drugs Phase 3: 1 Phase 2: 2
Infectious Disease 3%
0 drugs Phase 3: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease, Neurology
Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
AbbVie big-pharma
Oncology, Neurology, Infectious Disease
GSK big-pharma
Infectious Disease, Oncology, Neurology
Takeda big-pharma
Oncology, Gastroenterology, Neurology
Discontinued (2)
Company Info
- First Approval
- 2004-02-10
- Latest
- 2025-10-02
- Applications
- 4